BR0214753A - 4-feniltetrahidroisoquinolinas, substituìdas, processos para a sua preparação, sua aplicação como medicamento, bem como, medicamento contendo as mesmas - Google Patents

4-feniltetrahidroisoquinolinas, substituìdas, processos para a sua preparação, sua aplicação como medicamento, bem como, medicamento contendo as mesmas

Info

Publication number
BR0214753A
BR0214753A BR0214753-0A BR0214753A BR0214753A BR 0214753 A BR0214753 A BR 0214753A BR 0214753 A BR0214753 A BR 0214753A BR 0214753 A BR0214753 A BR 0214753A
Authority
BR
Brazil
Prior art keywords
medicine
processes
preparation
application
same
Prior art date
Application number
BR0214753-0A
Other languages
English (en)
Inventor
Armin Hofmeister
Uwe Heinelt
Hans-Jochen Lang
Markus Bleich
Klaus Wirth
Michael Gekle
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0214753A publication Critical patent/BR0214753A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18Aralkyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"4-FENILTETRAHIDROISOQUINOLINAS, SUBSTITUìDAS, PROCESSOS PARA A SUA PREPARAçãO, SUA APLICAçãO COMO MEDICAMENTO, BEM COMO MEDICAMENTO CONTENDO AS MESMAS". Compostos da fórmula (1), na qual R1 até R9 têm os significados dados nas reivindicações, são acentuadamente adequados com antihipertensivos para diminuir ou impedir estados induzidos isquemicamente, como medicamentos para intervenções cirúrgicas para o tratamento de isquemias do sistema nervoso, do ataque de apoplexia e do edema cerebral, do choque, do estímulo respiratório perturbado, para o tratamento do ronco, como laxante, como agente contra ectoparasitas, para a prevenção contra a formação de cálculos biliares, como antiateroscleróticos, agentes contra complicações tardias do diabetes, doenças de câncer, doenças fibróticas, disfunção endotelial, hipertrofias e hiperplasias de órgãos. Eles são inibidores do trocador de sódio-prótons celular. Eles influenciam as lipoproteínas do soro e podem ser empregados, por conseguinte, para a profilaxia e para a regressão de alterações ateroscleróticas.
BR0214753-0A 2001-12-05 2002-11-20 4-feniltetrahidroisoquinolinas, substituìdas, processos para a sua preparação, sua aplicação como medicamento, bem como, medicamento contendo as mesmas BR0214753A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10159714 2001-12-05
PCT/EP2002/012990 WO2003048129A1 (de) 2001-12-05 2002-11-20 Substituierte 4-phenyltetrahydroisochinoline, verfahren zu ihrer herstellung, ihre verwendung als medikament, sowie sie enthaltendes medikament

Publications (1)

Publication Number Publication Date
BR0214753A true BR0214753A (pt) 2004-12-14

Family

ID=7708117

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214753-0A BR0214753A (pt) 2001-12-05 2002-11-20 4-feniltetrahidroisoquinolinas, substituìdas, processos para a sua preparação, sua aplicação como medicamento, bem como, medicamento contendo as mesmas

Country Status (34)

Country Link
EP (1) EP1453810B1 (pt)
JP (1) JP4510457B2 (pt)
KR (1) KR20050044724A (pt)
CN (1) CN100497314C (pt)
AR (1) AR037620A1 (pt)
AT (1) ATE425968T1 (pt)
AU (1) AU2002356689B2 (pt)
BR (1) BR0214753A (pt)
CA (1) CA2469385A1 (pt)
CO (1) CO5580748A2 (pt)
DE (1) DE50213372D1 (pt)
DK (1) DK1453810T3 (pt)
EC (1) ECSP045138A (pt)
ES (1) ES2324528T3 (pt)
HK (1) HK1072597A1 (pt)
HR (1) HRP20040507A2 (pt)
HU (1) HUP0600854A2 (pt)
IL (1) IL162316A0 (pt)
MA (1) MA27147A1 (pt)
MX (1) MXPA04005343A (pt)
MY (1) MY157371A (pt)
NO (1) NO326650B1 (pt)
NZ (1) NZ533322A (pt)
OA (1) OA12740A (pt)
PE (1) PE20030726A1 (pt)
PL (1) PL369313A1 (pt)
PT (1) PT1453810E (pt)
RS (1) RS48004A (pt)
RU (1) RU2298003C2 (pt)
TN (1) TNSN04100A1 (pt)
TW (1) TWI281860B (pt)
UA (1) UA77042C2 (pt)
WO (1) WO2003048129A1 (pt)
ZA (1) ZA200403711B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
DE102004046492A1 (de) * 2004-09-23 2006-03-30 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
DE102005001411A1 (de) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
CA2598423C (en) 2005-02-18 2014-05-27 Astrazeneca Ab Antibacterial piperidine derivatives
JP2008531671A (ja) * 2005-03-04 2008-08-14 アストラゼネカ アクチボラグ 化合物
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102006012545A1 (de) 2006-03-18 2007-09-27 Sanofi-Aventis Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
WO2018129556A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP3351248B1 (en) 2008-12-31 2021-06-09 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
KR102138391B1 (ko) * 2012-08-21 2020-07-27 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료에서 nhe-매개된 역수송 저해를 위한 화합물 및 방법
EP3552630A1 (en) 2013-04-12 2019-10-16 Ardelyx, Inc. Nhe3-binding compounds for inhibiting phosphate transport
CN103788084A (zh) * 2014-03-02 2014-05-14 湖南华腾制药有限公司 四氢异喹啉衍生物及其合成方法
RU2703456C2 (ru) * 2014-07-25 2019-10-17 Тайсо Фармасьютикал Ко., Лтд. Фенилтетрагидроизохинолиновое соединение, замещенное гетероарилом
JP6903923B2 (ja) * 2016-01-22 2021-07-14 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物を有効成分として含有する医薬
CA3049678A1 (en) * 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport
TWI805137B (zh) * 2020-12-18 2023-06-11 大陸商上海濟煜醫藥科技有限公司 苯并雜環取代四氫異喹啉類化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951702A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
AU784280B2 (en) * 1999-11-03 2006-03-02 Albany Molecular Research, Inc. 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
DE60038185T2 (de) * 1999-11-03 2009-02-19 Amr Technology, Inc. Arly- und heteroaryl-substituierte tetrahydroisoquinoline und ihre verwendung als hemmer der wiederaufnahme von norepinephrin, dopamin und serotonin
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
DE10019062A1 (de) * 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren

Also Published As

Publication number Publication date
HK1072597A1 (en) 2005-09-02
WO2003048129A1 (de) 2003-06-12
DK1453810T3 (da) 2009-07-20
TNSN04100A1 (en) 2006-06-01
EP1453810B1 (de) 2009-03-18
RU2004120295A (ru) 2006-01-10
PL369313A1 (en) 2005-04-18
AU2002356689B2 (en) 2008-05-15
AR037620A1 (es) 2004-11-17
HRP20040507A2 (en) 2005-08-31
CO5580748A2 (es) 2005-11-30
TW200306190A (en) 2003-11-16
TWI281860B (en) 2007-06-01
OA12740A (en) 2006-06-30
NZ533322A (en) 2006-02-24
UA77042C2 (en) 2006-10-16
NO326650B1 (no) 2009-01-26
MA27147A1 (fr) 2005-01-03
AU2002356689A1 (en) 2003-06-17
ES2324528T3 (es) 2009-08-10
KR20050044724A (ko) 2005-05-12
NO20042158L (no) 2004-08-27
PE20030726A1 (es) 2003-09-30
JP2005515205A (ja) 2005-05-26
CN100497314C (zh) 2009-06-10
HUP0600854A2 (en) 2007-02-28
MXPA04005343A (es) 2004-09-27
JP4510457B2 (ja) 2010-07-21
CN1617856A (zh) 2005-05-18
MY157371A (en) 2016-06-15
ECSP045138A (es) 2004-08-27
RU2298003C2 (ru) 2007-04-27
PT1453810E (pt) 2009-05-27
EP1453810A1 (de) 2004-09-08
ATE425968T1 (de) 2009-04-15
IL162316A0 (en) 2005-11-20
RS48004A (en) 2006-10-27
CA2469385A1 (en) 2003-06-12
DE50213372D1 (de) 2009-04-30
ZA200403711B (en) 2005-06-09

Similar Documents

Publication Publication Date Title
BR0214753A (pt) 4-feniltetrahidroisoquinolinas, substituìdas, processos para a sua preparação, sua aplicação como medicamento, bem como, medicamento contendo as mesmas
DE3856442T2 (de) Verwendung von sulfatierten Zuckern gegen Entzundung
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
DE50211204D1 (de) Cannabis extrakten pharmazeutische zusammensetzung
BR9910801A (pt) Derivados da pirazolina, a preparação dos mesmose a aplicação dos mesmos como um medicamento
BR0113358A (pt) Derivado de quinazolina ou de um seu sal farmaceuticamente aceitável, processo para a sua preparação, composição farmacêutica, e, uso do derivado ou de um seu sal farmaceuticamente aceitável
IS6647A (is) Kínasólínafleiður til að meðhöndla æxli
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
MXPA00009705A (es) Uso de poliaminas en el tratamiento de sintomas dermatologicos.
BR0116605A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
EP1246629A1 (en) Methods of using electron active compounds for managing cancer
BR9911861A (pt) Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
EA200801698A1 (ru) Лекарственные композиции для применения в вагине
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
BR0016360A (pt) Derivados de norbornilamino substituìdos, processos para a sua preparação, seu emprego como medicamento ou diagnóstico bem como medicamento contendo os mesmos
US20060240119A1 (en) Pharmacologically active strong acid solutions
Hasinoff et al. The effect of dexrazoxane (ICRF-187) on doxorubicin-and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells
DE60105452D1 (de) Sucralfat enthaltendes arzneimittel zur behandlung von zervikale erosion
US3705239A (en) Pain removing compositions and methods
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
Zeenat et al. An appraisal of medicinal properties of Shibb-e-Yamani (Alum): a review
PE20030721A1 (es) Sales de 4-feniltetrahidroisoquinolinio sustituidas, procedimiento para su preparacion, su uso como medicamentos y medicamento que las contiene
RU2368609C1 (ru) Серебряная соль n-(6-метил-2,4-диоксо-1,2,3,4-тетрагидро-5h-пиримидинсульфон)-n'-изоникотиноилгидразида, проявляющая иммунотропную, противомикробную, противогрибковую (противомикотическую) активность, и лекарственное средство на ее основе

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.